Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Recent Press Releases

5/8/2013 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2013
3/18/2013 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2012
3/4/2013 Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection® in Argentina

2/4/2013 Hemispherx Biopharma Receives Complete Response Letter from FDA on Ampligen® New Drug Application for Chronic Fatigue Syndrome …Hemispherx will seek an End-of-Review Conference with the FDA

12/21/2012 FDA Advisory Committee Makes Recommendations on Ampligen® for Chronic Fatigue Syndrome
11/2/2012 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2012
….. AMPLIGEN® NEW DRUG APPLICATION AND PRE-APPROVAL INSPECTION ARE TOP PRIORITIES….
10/22/2012 Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
… Arthritis Advisory Committee Will Review Ampligen® for Chronic Fatigue Syndrome
10/1/2012 Hemispherx Biopharma Files for Treatment Expansion in Argentina for Alferon N Injection® for Hepatitis C

9/24/2012 Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen® for Chronic Fatigue Syndrome … Advisory Committee Meeting Tentatively Scheduled for December 20, 2012

9/19/2012 Hemispherx Biopharma Reports on Annual Stockholder Meeting
 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.